Wednesday, July 8, 2026

pharma · Irritable Bowel Syndrome With Constipation · Chronic Constipation · IRWD

IRONWOOD PHARMACEUTICALS

IRONWOOD PHARMACEUTICALS clinical programs — 33 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

100 Summer Street, Boston, MA 02110, US HQ
1998 Founded
262 Employees
Public company Type
IRWD · NYSE Ticker
Company details
Status
Public
HQ
100 Summer Street, Boston, MA 02110, US
Founded
1998
Employees
262
Programs
33
Drugs
11
Patents
45
Intelligence · Clinical Programs

IRONWOOD PHARMACEUTICALS projects

33 ClinicalTrials.gov programs sponsored by IRONWOOD PHARMACEUTICALS.

IRONWOOD PHARMACEUTICALS has 33 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. IW-3718

    IRONWOOD PHARMACEUTICALS INC

    Gastroesophageal Reflux Disease (GERD)

    phase 3 small molecule terminated

    2 trials
  2. LIN-MD-66

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome With Constipation

    phase 3 small molecule completed

    1 trial
  3. Linaclotide

    IRONWOOD PHARMACEUTICALS INC

    Chronic Idiopathic Constipation

    phase 3 small molecule completed

    1 trial
  4. Linaclotide

    IRONWOOD PHARMACEUTICALS INC

    Functional Constipation

    phase 3 small molecule completed

    3 trials
  5. Linaclotide

    IRONWOOD PHARMACEUTICALS INC

    Chronic Constipation

    phase 3 small molecule completed

    1 trial
  6. Linaclotide 290 micrograms

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome Characterized by Constipation

    phase 3 small molecule completed

    1 trial
  7. Linaclotide 290 micrograms

    IRONWOOD PHARMACEUTICALS INC

    Chronic Constipation

    phase 3 small molecule completed

    2 trials
  8. Linaclotide or Matching Placebo

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome With Constipation

    phase 3 small molecule completed

    1 trial
  9. Matching Placebo

    IRONWOOD PHARMACEUTICALS INC

    Chronic Constipation

    phase 3 small molecule completed

    1 trial
  10. Placebo

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome With Constipation (IBS-C)

    phase 3 small molecule completed

    1 trial
  11. Placebo for Linaclotide

    IRONWOOD PHARMACEUTICALS INC

    Functional Constipation (FC)

    phase 3 small molecule completed

    1 trial
  12. IW-3300 rectal foam

    IRONWOOD PHARMACEUTICALS INC

    Interstitial Cystitis

    phase 2 small molecule terminated

    1 trial
  13. IW-3718

    IRONWOOD PHARMACEUTICALS INC

    Gastroesophageal Reflux Disease

    phase 2 small molecule completed

    1 trial
  14. IW-3718

    IRONWOOD PHARMACEUTICALS INC

    Gastroesophageal Reflux

    phase 2 small molecule completed

    1 trial
  15. IW-6118

    IRONWOOD PHARMACEUTICALS INC

    Healthy

    phase 2 small molecule completed

    1 trial
  16. IW-9179

    IRONWOOD PHARMACEUTICALS INC

    Dyspepsia

    phase 2 small molecule terminated

    1 trial
  17. IW-9179

    IRONWOOD PHARMACEUTICALS INC

    Diabetic Gastroparesis

    phase 2 small molecule completed

    1 trial
  18. Linaclotide 145 micrograms

    IRONWOOD PHARMACEUTICALS INC

    Opioid-Induced Constipation

    phase 2 small molecule completed

    1 trial
  19. Linaclotide Acetate

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome With Constipation

    phase 2 small molecule completed

    1 trial
  20. Linaclotide Dose A

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome With Constipation

    phase 2 small molecule terminated

    1 trial
  21. MD-0727

    IRONWOOD PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule completed

    1 trial
  22. MD-1100 Acetate

    IRONWOOD PHARMACEUTICALS INC

    Constipation

    phase 2 small molecule completed

    1 trial
  23. MD-1100 Acetate

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome

    phase 2 small molecule completed

    1 trial
  24. MD-7246

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome With Diarrhea (IBS-D)

    phase 2 small molecule completed

    1 trial
  25. Placebo

    IRONWOOD PHARMACEUTICALS INC

    Functional Constipation in Children Ages 6-17 Years

    phase 2 small molecule completed

    1 trial
  26. linaclotide acetate

    IRONWOOD PHARMACEUTICALS INC

    Chronic Constipation

    phase 2 small molecule completed

    1 trial
  27. IW-3300

    IRONWOOD PHARMACEUTICALS INC

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials
  28. Microgestin®

    IRONWOOD PHARMACEUTICALS INC

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  29. Lesinurad

    IRONWOOD PHARMACEUTICALS INC

    Gout

    approved small molecule terminated

    1 trial
  30. Linaclotide

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome Characterized by Constipation

    approved small molecule completed

    2 trials
  31. Linaclotide

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome With Constipation

    approved small molecule completed

    3 trials
  32. 7 g Ispaghula

    IRONWOOD PHARMACEUTICALS INC

    Healthy

    other completed

    1 trial
  33. Ispaghula

    IRONWOOD PHARMACEUTICALS INC

    Constipation

    other completed

    1 trial

Frequently asked questions

How many clinical projects does IRONWOOD PHARMACEUTICALS have?

33 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.